Evidence dossier · candidate cand-mmr-anaphylaxis · VICP program · · DRAFT — not a determination
This is a draft research-tracking dossier, not a determination that MMR vaccine causes Anaphylaxis, and not an incidence or legal finding. All evidence is flagged needs_human_review and must be reviewed before any page is published or cited. Every value is grounded in retrieved citations (PMID + retrieval date); unsourced items read "no evidence found / not assessable". Symmetric search: every supporting query has a mirror/null query, and zeros are shown (negative dossiers report the absence of signal).
Claim matrix (C1–C6, computed)
Claim
Label
Status
Missing nodes
C1
Coherent clinical object exists
insufficient_data
missing: A1 A2
C2
Consistent temporal window
supported
C3
Epidemiologic excess risk
insufficient_data
missing: B1 B2 B3
C4
Consistency / replication
insufficient_data
missing: B5
C5
Specificity (product / dose)
insufficient_data
missing: C1n
C6
Biological mechanism
insufficient_data
missing: E1
Two evidentiary bars apply to the epi nodes/claims (C3, C4): · VICP — preponderance of the evidence. · CICP (off-Table) — compelling, reliable, valid medical and scientific evidence (higher bar).
Bradford Hill assessment (computed)
Each viewpoint is derived from the node statuses below (see the framework crosswalk in compensation-tables-schema.md §8). Hill's viewpoints are aids to judgement, not a scoring checklist that proves causation; temporality is the only strictly necessary criterion.
Viewpoint
What it asks
Status (from evidence)
Temporality(necessary)
cause precedes effect in a plausible window (necessary)
NASEM (formerly IOM), "Adverse Effects of Vaccines: Evidence and Causality" (2011, updated 2024). Independent grading of epidemiologic and mechanistic evidence, synthesized into one of four causal-conclusion categories. This is a computed approximation of that framework, not a NASEM determination. See compensation-tables-schema.md §8bis.
Case-definition standard: Brighton Collaboration (named in spec §1: anaphylaxis) — governs the case-certainty scale on A1/A2/A6/A8 below. See compensation-tables-schema.md §8ter.
Evidence matrix (68 nodes by workstream)
68 of 68 nodes evaluated · 136 PubMed queries logged (supporting + mirror, incl. zeros). Statuses are computed from retrieved citations; not hand-set.
Definition & attribution 24/24 evaluated
A1 · Case reportsno_data
Measure: New definite object in risk window T Comparator: Pre-vaccination baseline Hit rule: Definite object present, onset in window, competing causes considered
Finding: No retrieved evidence addresses MMR vaccine and anaphylaxis. All retrieved studies concern SARS-CoV-2, COVID-19, HPV, monkeypox, or other vaccines, not MMR vaccine.
Cited: (none)
supporting: MMR vaccine Anaphylaxis case report OR case series Case reports pubmed · 66171 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
11 retrieved record(s)
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 37267449 · The Gerontologist (2024) — Using Twitter to Understand COVID-19 Vaccine-Related Ageism During the Pandemic.
does_not_resolve 35251812 · Cureus (2022) — COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports.
does_not_resolve 37991289 · Indian journal of ophthalmology (2023) — COVID and COVID vaccine-related corneal morbidity: A review.
A2 · Series with objective confirmationno_data
Measure: Definite object plus objective test Comparator: Reference range / diagnostic criteria Hit rule: Objective confirmation in >=1 case per the working definition
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis case report OR case series Series with objective confirmation pubmed · 5652 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
10 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 40927603 · Journal of healthcare, science and the h (2024) — The Effects of Covid-19 Vaccination on Menstruation: Are women with underlying reproductive health conditions, particularly black women at a higher risk for vac
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 35251812 · Cureus (2022) — COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports.
A3 · Onset histogramsupports
Measure: Distribution of onset times after dose Comparator: Pre-specified risk window Hit rule: Onset clusters inside the pre-specified window (not uniform/flat)
Finding: Retrieved case reports document anaphylaxis to MMR vaccine occurring within minutes to hours after vaccination, with onset temporally clustered post-dose, supporting a non-uniform onset distribution within a pre-specified risk window.
supporting: MMR vaccine Anaphylaxis case report OR case series Onset histogram pubmed · 13 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
21 retrieved record(s)
supports_node 32395766 · Military medicine (2020) — Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin.
does_not_resolve 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
ambiguous 1593346 · The Journal of pediatrics (1992) — Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine.
ambiguous 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
ambiguous 27986511 · The Journal of allergy and clinical immu (2017) — Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism.
supports_node 12456938 · Pediatrics (2002) — Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
ambiguous 29913263 · The journal of allergy and clinical immu (2019) — Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy.
supports_node 21244488 · Acta paediatrica (Oslo, Norway : 1992) (2011) — Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk.
A4 · Temporal plausibilitysupports
Measure: Onset latency vs object pathophysiology Comparator: Object's known natural latency Hit rule: Onset latency consistent with the object's pathophysiology
Finding: A single case report describes anaphylaxis to MMR vaccine in a recruit sensitized to gelatin IgE, with onset timing consistent with an IgE-mediated reaction pathophysiology (i.e., minutes to hours after vaccination).
supporting: MMR vaccine Anaphylaxis case report OR case series Temporal plausibility pubmed · 42 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 15638050 · Clinical and experimental rheumatology (2004) — A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adv
supports_node 32395766 · Military medicine (2020) — Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 35251812 · Cureus (2022) — COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports.
A5 · Onset-interval documentationmixed
Measure: Onset interval documented in source Comparator: Dose date Hit rule: Onset interval is recorded (not imputed) in a primary source
Finding: Several case reports describe anaphylaxis after MMR vaccination with documented onset intervals (e.g., within minutes to hours) in primary sources, but no study systematically reports or quantifies onset-interval documentation as a formal measure.
supporting: MMR vaccine Anaphylaxis case report OR case series Onset-interval documentation pubmed · 11 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
21 retrieved record(s)
supports_node 32395766 · Military medicine (2020) — Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin.
supports_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
does_not_resolve 1593346 · The Journal of pediatrics (1992) — Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine.
supports_node 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
ambiguous 27986511 · The Journal of allergy and clinical immu (2017) — Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism.
does_not_resolve 12456938 · Pediatrics (2002) — Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
ambiguous 29913263 · The journal of allergy and clinical immu (2019) — Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy.
supports_node 21244488 · Acta paediatrica (Oslo, Norway : 1992) (2011) — Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk.
A6 · Differential diagnosis excludedno_data
Measure: Competing causes assessed and excluded Comparator: Likely alternative diagnoses Hit rule: Pre-specified competing causes ruled out per the working definition
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis case report OR case series Differential diagnosis excluded pubmed · 438 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 33661194 · Clinical nuclear medicine (2021) — COVID-19 Vaccine-Related Local FDG Uptake.
does_not_resolve 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
does_not_resolve 35251812 · Cureus (2022) — COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports.
A7 · Rechallenge / re-exposuresupports
Measure: Object recurs on a further dose Comparator: First-dose response Hit rule: Object recurs after a subsequent dose (re-exposure)
Finding: Two case reports describe anaphylaxis recurrence upon MMR re-exposure: PMID 8473675 describes a patient who had an uneventful primary MMR at 15 months but developed anaphylaxis after a subsequent dose at age 17; PMID 28318190 reports successful graded challenge administration of MMR in a patient with prior anaphylaxis to the vaccine, implying recurrence risk on re-exposure.
supporting: MMR vaccine Anaphylaxis case report OR case series Rechallenge / re-exposure pubmed · 13 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
21 retrieved record(s)
supports_node 32395766 · Military medicine (2020) — Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin.
supports_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
does_not_resolve 1593346 · The Journal of pediatrics (1992) — Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine.
supports_node 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
supports_node 27986511 · The Journal of allergy and clinical immu (2017) — Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism.
supports_node 12456938 · Pediatrics (2002) — Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
ambiguous 29913263 · The journal of allergy and clinical immu (2019) — Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy.
supports_node 21244488 · Acta paediatrica (Oslo, Norway : 1992) (2011) — Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk.
A8 · Adjudicated by criteria (Brighton Collaboration)no_data
Measure: Object adjudicated by published criteria Comparator: Published clinical / Brighton criteria Hit rule: Cases adjudicated to 'definite' by a published criterion set
Finding: No retrieved evidence addresses MMR vaccine-related anaphylaxis; available studies discuss COVID-19 vaccine adverse events, anaphylaxis in a pediatric ED without vaccine attribution, or unrelated topics.
Cited: (none)
supporting: MMR vaccine Anaphylaxis case report OR case series Adjudicated by criteria pubmed · 50 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 28390586 · Annals of allergy, asthma & immunology : (2017) — An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year period.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 40927603 · Journal of healthcare, science and the h (2024) — The Effects of Covid-19 Vaccination on Menstruation: Are women with underlying reproductive health conditions, particularly black women at a higher risk for vac
A9 · Natural-history consistencyno_data
Measure: Course matches the object's natural history Comparator: Known natural history of the object Hit rule: Clinical course (onset, peak, recovery) matches the object's natural history
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis case report OR case series Natural-history consistency pubmed · 114 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
11 retrieved record(s)
does_not_resolve 23041539 · Clinical gastroenterology and hepatology (2012) — Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 33661194 · Clinical nuclear medicine (2021) — COVID-19 Vaccine-Related Local FDG Uptake.
does_not_resolve 37267449 · The Gerontologist (2024) — Using Twitter to Understand COVID-19 Vaccine-Related Ageism During the Pandemic.
A10 · No confounding objectmixed
Measure: Not attributable to a co-occurring condition Comparator: Co-occurring illness that could produce the object Hit rule: Object not better explained by a co-occurring condition (infection, etc.)
Finding: There are two case reports of anaphylaxis to MMR vaccine mediated by IgE sensitivity to gelatin, with no evidence assessing whether the anaphylaxis was better explained by a co-occurring condition.
supporting: MMR vaccine Anaphylaxis case report OR case series No confounding object pubmed · 30 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 34312836 · Clinical pharmacology and therapeutics (2022) — Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
supports_node 32395766 · Military medicine (2020) — Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin.
refutes_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
D1 · Predicted site of injuryno_data
Measure: Object at the site the mechanism predicts Comparator: Predicted anatomic site from the mechanism Hit rule: Object localizes to the anatomic site the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis anatomic localization Predicted site of injury mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Predicted site of injury not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D2 · Spared structuresno_data
Measure: Structures the mechanism should spare are spared Comparator: Structures predicted unaffected Hit rule: Structures predicted spared by the mechanism are indeed spared
mirror: MMR vaccine Anaphylaxis Spared structures not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D3 · Local vs systemic distributionno_data
Measure: Distribution matches mechanism scope Comparator: Local (injection site) vs systemic expectation Hit rule: Observed distribution (local vs systemic) matches the mechanism's predicted scope
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis anatomic localization Local vs systemic distribution mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Local vs systemic distribution not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D4 · Kinetics classno_data
Measure: Onset/offset kinetics match the mechanism Comparator: Expected kinetic class (acute vs chronic) Hit rule: Onset and offset kinetics are in the class the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis anatomic localization Kinetics class mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Kinetics class not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D5 · Platform-mechanism matchno_data
Measure: Mechanism is consistent with the platform Comparator: Mechanistic expectation for the platform Hit rule: The proposed mechanism is biologically consistent with the vaccine platform
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis anatomic localization Platform-mechanism match mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Platform-mechanism match not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
H3 · Targeted treatment reversesno_data
Measure: A targeted treatment reverses the object in patients Comparator: Treatment-naive / placebo Hit rule: A mechanism-directed treatment reverses the object (vs control treatment)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Targeted treatment reverses intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
Measure: No node's finding contradicts another Comparator: Internal consistency across nodes Hit rule: No evaluated node directly contradicts another (coherence)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis No internal contradiction coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis No internal contradiction inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
I2 · Analogy to a known objectno_data
Measure: Object analogous to a well-established analog Comparator: Established analog's profile Hit rule: The object's profile matches a well-established analog on key features
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Analogy to a known object coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Analogy to a known object inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
I5 · Latency coherenceno_data
Measure: Observed latency matches the mechanism's latency Comparator: Mechanism-predicted latency Hit rule: Observed onset latency is coherent with the mechanism's predicted latency
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Latency coherence coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Latency coherence inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
J1 · Pre-specificationno_data
Measure: Window/hit-rule pre-specified before data Comparator: Pre-specified vs post-hoc Hit rule: The risk window, object, and hit rule were pre-specified before data were seen
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Pre-specification pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Pre-specification post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
J2 · Contrary-evidence logno_data
Measure: Contrary evidence is logged, not omitted Comparator: Support-only dossier Hit rule: Contrary / null / refuting findings are logged and shown alongside support
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Contrary-evidence log pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Contrary-evidence log post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
Measure: Claim not based on temporality alone Comparator: Sequence-only evidence Hit rule: The claim is not supported by temporal sequence alone (independent evidence exists)
Finding: The retrieved evidence focuses on using large language models to identify immune-related adverse events in patients receiving immune checkpoint inhibitors, with no mention of MMR vaccine or anaphylaxis.
Cited: (none)
supporting: MMR vaccine Anaphylaxis No temporality-only claim pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis No temporality-only claim post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
J4 · Passive-surveillance roleno_data
Measure: Passive-surveillance findings bounded correctly Comparator: Active-surveillance confirmation Hit rule: Passive-surveillance signals are framed as hypothesis-generating, not confirmatory
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Passive-surveillance role pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Passive-surveillance role post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 35412949 · Human vaccines & immunotherapeutics (2022) — Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating in-silico approach.
J5 · Dose mappingno_data
Measure: Dose/lot exposure mapped to the object Comparator: Unmapped exposure Hit rule: Dose / lot exposure is mapped to the object where the mechanism predicts it
Finding: No evidence retrieved that links MMR vaccine dose exposure to anaphylaxis; the retrieved articles address immune-related adverse events from immune checkpoint inhibitors (PMID 39226489) and COVID-19 vaccine-induced thrombotic events (PMID 35412949), neither of which pertains to MMR vaccine or anaphylaxis.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Dose mapping pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Dose mapping post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 35412949 · Human vaccines & immunotherapeutics (2022) — Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating in-silico approach.
Epidemiologic chassis 13/13 evaluated
B1 · Excess vs baselineno_data
Measure: RR/IRR vs unexposed or prior window Comparator: Unvaccinated person-time or pre-vaccination window Hit rule: RR/IRR > 1 with CI excluding 1 after pre-specified confounders
Finding: The retrieved evidence contains no studies evaluating the risk of anaphylaxis following MMR vaccination; the studies focus on other vaccines (e.g., COVID-19, BNT162b2) or other outcomes (e.g., acute kidney injury, mortality, Guillain-Barré syndrome, arrhythmias, stroke).
Cited: (none)
supporting: MMR vaccine Anaphylaxis Excess vs baseline incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Excess vs baseline pubmed · 88487 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 34672967 · Lancet (London, England) (2021) — Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, pha
B2 · SCCSno_data
Measure: Self-controlled case series risk ratio Comparator: Individuals' own risk intervals (no-event) Hit rule: SCCS risk ratio > 1 in the post-vaccination window, CI excluding 1
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis SCCS incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk SCCS pubmed · 88595 hits · run 2026-09-07
12 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 39795956 · International journal of molecular scien (2024) — The Potential Metalloestrogenic Effect of Aluminum on Breast Cancer Risk for Antiperspirant Users.
B3 · Cohort / risk-intervalno_data
Measure: Incidence rate ratio in defined window Comparator: Pre-specified risk vs comparison interval Hit rule: IRR > 1 in the pre-specified window, CI excluding 1, stratified by age/sex
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Cohort / risk-interval incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Cohort / risk-interval pubmed · 88096 hits · run 2026-09-07
12 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 33748963 · British journal of haematology (2021) — Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
does_not_resolve 37806668 · Human vaccines & immunotherapeutics (2023) — Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-a
does_not_resolve 41284649 · PloS one (2025) — Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
does_not_resolve 26004568 · Vaccine (2015) — Deaths following vaccination: What does the evidence show?
B4 · Meta-analysis / poolingno_data
Measure: Pooled effect across studies Comparator: Pooled estimate with heterogeneity Hit rule: Pooled estimate > 1 (or < 1) with quantified heterogeneity (I2)
Finding: No retrieved evidence directly addresses a pooled estimate for anaphylaxis following MMR vaccination. The only meta-analysis that includes anaphylaxis [PMID 40664645] evaluates XBB.1.5-containing COVID-19 mRNA vaccines, not the MMR vaccine.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Meta-analysis / pooling incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Meta-analysis / pooling pubmed · 111927 hits · run 2026-09-07
12 retrieved record(s)
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
B5 · Negative-control outcomesno_data
Measure: No excess for outcomes the vaccine should not cause Comparator: Negative-control outcomes (unaffected by mechanism) Hit rule: Null for negative-control outcomes while target outcome is positive (specificity)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Negative-control outcomes incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Negative-control outcomes pubmed · 88298 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
ambiguous 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 33748963 · British journal of haematology (2021) — Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
does_not_resolve 36813998 · Eye (London, England) (2023) — Risk of retinal vein occlusion following COVID-19 vaccination: a self-controlled case series.
does_not_resolve 37806668 · Human vaccines & immunotherapeutics (2023) — Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-a
B6 · Other-antigen comparisonno_data
Measure: Risk vs a different-antigen comparator Comparator: Comparator product with a different antigen Hit rule: Risk specific to the target antigen, not shared with the comparator antigen
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Other-antigen comparison incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Other-antigen comparison pubmed · 88060 hits · run 2026-09-07
14 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 33748963 · British journal of haematology (2021) — Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
does_not_resolve 36813998 · Eye (London, England) (2023) — Risk of retinal vein occlusion following COVID-19 vaccination: a self-controlled case series.
does_not_resolve 37806668 · Human vaccines & immunotherapeutics (2023) — Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-a
B7 · Absolute riskno_data
Measure: Per-100k risk in window Comparator: Absolute incidence per 100k Hit rule: Absolute risk reported and stable across the window (not an artifact of rarity)
Finding: No evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Absolute risk incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Absolute risk pubmed · 111327 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 29211679 · The New England journal of medicine (2017) — Contemporary Hormonal Contraception and the Risk of Breast Cancer.
B8 · Platform splitno_data
Measure: Risk by vaccine platform / product Comparator: Platform (mRNA vs viral vector, etc.) Hit rule: Risk attributable to a specific platform, not to 'a vaccine' generally
Finding: No evidence found.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Platform split incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Platform split pubmed · 88125 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 36370744 · The Lancet. Child & adolescent health (2023) — Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
B9 · Host-structure stratificationno_data
Measure: Risk by age / sex / host structure Comparator: Unstratified estimate Hit rule: Risk concentrated in a defined host subgroup (e.g. young males), stable across sources
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Host-structure stratification incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Host-structure stratification pubmed · 88058 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 37534766 · Human vaccines & immunotherapeutics (2023) — Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 42661284 · Expert review of vaccines (2026) — Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 26004568 · Vaccine (2015) — Deaths following vaccination: What does the evidence show?
B10 · Formulation / component changeno_data
Measure: Risk tracks a formulation change Comparator: Pre- vs post-change formulation Hit rule: Risk change tracks a documented formulation / component change over time
Finding: No retrieved evidence pertains to MMR vaccine, anaphylaxis, or formulation/component changes affecting risk; all retrieved studies address unrelated vaccines (COVID-19, influenza, antibiotics) or outcomes (acute kidney injury, Guillain-Barré syndrome, arrhythmias, venous thromboembolism, mortality) in different contexts.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Formulation / component change incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no association OR null OR no increased risk Formulation / component change pubmed · 88220 hits · run 2026-09-07
8 retrieved record(s)
does_not_resolve 29961876 · Nephrology, dialysis, transplantation : (2019) — Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 33748963 · British journal of haematology (2021) — Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
does_not_resolve 37806668 · Human vaccines & immunotherapeutics (2023) — Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-a
does_not_resolve 41092926 · Lancet (London, England) (2025) — Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 su
does_not_resolve 26004568 · Vaccine (2015) — Deaths following vaccination: What does the evidence show?
H2 · Formulation natural experimentno_data
Measure: Risk shifts with a formulation change in the field Comparator: Pre- vs post-change formulation Hit rule: Observed risk tracks a real-world formulation change (natural experiment)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Formulation natural experiment intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
does_not_resolve 16553322 · Revista do Instituto de Medicina Tropica (2005) — Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures.
H4 · Policy / pause signalno_data
Measure: Risk signal appears/disappears across a pause or policy change Comparator: Pre- vs post-pause period Hit rule: The signal appears or disappears coherently with a rollout / pause (H4)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Policy / pause signal intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Policy / pause signal no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-07
1 retrieved record(s)
does_not_resolve 38189107 · Expert review of vaccines (2024) — Neoadjuvant personalized cancer vaccines: the final frontier?
I3 · Infection coherenceno_data
Measure: Pattern is coherent with or distinct from infection Comparator: Infection-matched comparison Hit rule: The post-vaccine pattern is coherent with (or clearly distinct from) the infection pattern
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Infection coherence coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Infection coherence inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
Mediator & biological gradient 24/24 evaluated
C1n · Dose strength gradientno_data
Measure: Risk vs dose strength (dose size) Comparator: Lower dose strength Hit rule: Monotonic dose-response in dose strength (larger dose -> higher risk)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Dose strength gradient dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no dose effect OR no dose-response Dose strength gradient pubmed · 118 hits · run 2026-09-07
3 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
does_not_resolve 7708070 · The New England journal of medicine (1995) — Safe administration of the measles vaccine to children allergic to eggs.
C2n · Dose number gradientno_data
Measure: Risk vs dose number (1st vs 2nd vs 3rd) Comparator: First dose Hit rule: Risk increases (or shows a defined pattern) with dose number
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Dose number gradient dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no dose effect OR no dose-response Dose number gradient pubmed · 562 hits · run 2026-09-07
5 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
supports_node 7708070 · The New England journal of medicine (1995) — Safe administration of the measles vaccine to children allergic to eggs.
does_not_resolve 30316563 · Radiotherapy and oncology : journal of t (2019) — Volume effects of radiotherapy on the risk of second primary cancers: A systematic review of clinical and epidemiological studies.
does_not_resolve 42106826 · The international journal of behavioral (2026) — Physical activity, falls, and dementia risk in adults aged ≥ 60: evidence from three cohorts.
C3n · Measured-exposure tertilesno_data
Measure: Risk vs measured exposure tertile Comparator: Lowest-exposure tertile Hit rule: Risk ordered by measured-exposure tertile (high > mid > low)
Finding: The retrieved evidence includes case reports and series describing anaphylaxis after MMR vaccination, with some cases attributed to gelatin allergy rather than egg allergy, but no study measures risk across measured-exposure tertiles of a biomarker or dose.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Measured-exposure tertiles dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no dose effect OR no dose-response Measured-exposure tertiles pubmed · 7 hits · run 2026-09-07
9 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 28000606 · Diseases of aquatic organisms (2016) — Development of Streptococcus agalactiae vaccines for tilapia.
does_not_resolve 7708070 · The New England journal of medicine (1995) — Safe administration of the measles vaccine to children allergic to eggs.
supports_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
does_not_resolve 21361714 · Archives of Iranian medicine (2011) — Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.
does_not_resolve 42347632 · Vaccines (2026) — MMR Vaccination and Hen's Egg Allergy: Bridging the Gap Between Evidence and Clinical Practice.
ambiguous 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
ambiguous 28192490 · PloS one (2017) — Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China.
C4n · Organoid concentration curveno_data
Measure: Effect vs antigen concentration in organoid Comparator: Vehicle / zero antigen Hit rule: Dose-dependent effect across a graded concentration curve
Finding: No retrieved evidence provides dose-dependent effect data across a graded concentration curve for MMR vaccine and anaphylaxis in organoid models. The included studies focus on clinical case reports of anaphylaxis after MMR vaccination in children with egg or gelatin allergy, not on organoid concentration-response experiments.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Organoid concentration curve dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no dose effect OR no dose-response Organoid concentration curve pubmed · 18 hits · run 2026-09-07
7 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
does_not_resolve 7708070 · The New England journal of medicine (1995) — Safe administration of the measles vaccine to children allergic to eggs.
supports_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
does_not_resolve 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
ambiguous 21361714 · Archives of Iranian medicine (2011) — Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.
does_not_resolve 42347632 · Vaccines (2026) — MMR Vaccination and Hen's Egg Allergy: Bridging the Gap Between Evidence and Clinical Practice.
C5n · EC50 vs Cmax coherenceno_data
Measure: Measured exposure reaches effect threshold Comparator: Pharmacokinetic Cmax vs EC50 Hit rule: Achieved exposure (Cmax/tissue) plausibly reaches the in-vitro EC50
Finding: The retrieved evidence includes case reports of anaphylaxis following MMR vaccination, with some cases attributed to gelatin sensitivity rather than egg allergy, but none of the retrieved studies provide measured exposure (Cmax/tissue) data or in-vitro EC50 values to assess coherence between achieved exposure and the effect threshold.
Cited: (none)
supporting: MMR vaccine Anaphylaxis EC50 vs Cmax coherence dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis no dose effect OR no dose-response EC50 vs Cmax coherence pubmed · 7 hits · run 2026-09-07
9 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
does_not_resolve 7708070 · The New England journal of medicine (1995) — Safe administration of the measles vaccine to children allergic to eggs.
supports_node 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
supports_node 21361714 · Archives of Iranian medicine (2011) — Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.
refutes_node 42347632 · Vaccines (2026) — MMR Vaccination and Hen's Egg Allergy: Bridging the Gap Between Evidence and Clinical Practice.
does_not_resolve 28318190 · Archivos argentinos de pediatria (2017) — Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination.
does_not_resolve 28192490 · PloS one (2017) — Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China.
E1 · Mediator identified in casesno_data
Measure: Mediator present in affected tissue/cells Comparator: Unaffected tissue / control Hit rule: The hypothesized mediator is detected in the affected compartment and not (or less) in control
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Mediator identified in cases in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Mediator identified in cases not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E2 · Mediator in healthy vaccineesno_data
Measure: Mediator detectable after vaccination Comparator: Pre-vaccination baseline Hit rule: Mediator appears after vaccination and tracks the exposure window
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Mediator in healthy vaccinees in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Mediator in healthy vaccinees not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E3 · Infection contrastno_data
Measure: Mediator absent/low after natural infection Comparator: Recovered natural infection Hit rule: Mediator signal is specific to vaccination vs a comparable natural-infection control
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Infection contrast in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Infection contrast not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E4 · Transfer to recipientno_data
Measure: Phenotype/mediator transferred to a recipient system Comparator: Control transfer Hit rule: The effect / mediator transfers to a naive recipient system
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Transfer to recipient in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Transfer to recipient not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E5 · Transfer specificityno_data
Measure: Transfer requires the specific mediator Comparator: Transfer with mediator present Hit rule: Transfer effect is lost when the specific mediator is removed
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Transfer specificity in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Transfer specificity not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E6 · Depletion / knockdownno_data
Measure: Removing the mediator reduces the effect Comparator: Non-targeted knockdown Hit rule: Knockdown / depletion of the mediator reduces the phenotype
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Depletion / knockdown in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
Measure: Adding the mediator restores the effect Comparator: Add-back of a control protein Hit rule: Adding back the mediator (not a control) restores the phenotype
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Add-back rescue in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Add-back rescue not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E8 · Neutralizationno_data
Measure: Neutralizing the mediator blocks the effect Comparator: Isotype control Hit rule: Neutralization of the mediator (not an isotype control) blocks the phenotype
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Neutralization in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Neutralization not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E9 · Isotype controlno_data
Measure: Isotype control does not reproduce the effect Comparator: Active antibody Hit rule: An isotype control fails to reproduce the block/activation
Finding: The retrieved evidence does not address isotype control failure as a measure for anaphylaxis, but provides case-control and serological data linking anti-gelatin IgE antibodies to anaphylaxis after MMR vaccination, without any mention of isotype controls.
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Isotype control in vitro OR patient-derived pubmed · 29240 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Isotype control not associated mechanism pubmed · 5 hits · run 2026-09-07
5 retrieved record(s)
does_not_resolve 9847445 · The Journal of allergy and clinical immu (1998) — Gelatin-induced T-cell activation in children with nonanaphylactic-type reactions to vaccines containing gelatin.
supports_node 20339639 · Revista de saude publica (2010) — Anaphylaxis associated with the vaccine against measles, mumps and rubella.
supports_node 12456938 · Pediatrics (2002) — Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
supports_node 9949325 · The Journal of allergy and clinical immu (1999) — A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vac
supports_node 8977505 · The Journal of allergy and clinical immu (1996) — Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines.
F1 · Full product reproducesno_data
Measure: Full vaccine product reproduces the effect Comparator: No-product control Hit rule: The full product (not a subcomponent) reproduces the effect
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Full product reproduces component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Full product reproduces no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F2 · Empty vector / particleno_data
Measure: Vector/particle without antigen reproduces (or not) Comparator: Full product Hit rule: Effect attributed to (or excluded from) the vector/particle backbone alone
Finding: No retrieved evidence directly addresses the MMR vaccine vector or particle backbone alone causing anaphylaxis; the retrieved studies discuss virus-vectored vaccines for influenza, cancer, and Newcastle disease, and bacterial vaccine vectors, but none examine MMR vaccine or anaphylaxis from vector/particle without antigen.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Empty vector / particle component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 40276512 · Frontiers in immunology (2025) — Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.
F4 · Irrelevant cargono_data
Measure: Irrelevant cargo does not reproduce the effect Comparator: Vector with the target antigen Hit rule: Irrelevant cargo fails to reproduce the effect (specificity)
Finding: No retrieved evidence addresses anaphylaxis as an adverse event following MMR vaccination or evaluates whether irrelevant cargo (i.e., a non-MMR vaccine component) fails to reproduce anaphylaxis.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Irrelevant cargo component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F5 · Infection preparationno_data
Measure: Infection preparation vs product comparison Comparator: Product-derived preparation Hit rule: Effect compares correctly between infection and product preparations
Finding: The retrieved evidence discusses virus-vectored and live bacterial vaccine vectors, measles vaccine strains, and adenovirus-vectored vaccines, but none of the abstracts address anaphylaxis as an adverse event following MMR vaccination, nor do they compare infection preparation versus product preparation for anaphylaxis risk.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Infection preparation component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 40276512 · Frontiers in immunology (2025) — Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.
F6 · Cytokine / adjuvant mixno_data
Measure: Cytokine/adjuvant mix alone reproduces (or not) Comparator: Individual components Hit rule: The effect is (or is not) reproducible by the cytokine/adjuvant mix alone
Finding: No retrieved evidence discusses MMR vaccine or anaphylaxis, nor the reproducibility of anaphylaxis by a cytokine/adjuvant mix alone.
Cited: (none)
supporting: MMR vaccine Anaphylaxis Cytokine / adjuvant mix component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F7 · Component combinationsupports
Measure: Defined component combination reproduces the effect Comparator: Single components Hit rule: A defined combination reproduces the effect that single components do not
Finding: A case report (PMID 8473675) describes an anaphylactic reaction to MMR vaccine mediated by IgE to gelatin, which is a stabilizer component; the component combination (gelatin in MMR) reproduces the effect, as the individual components (MMR antigens alone) did not bind IgE in the same patient. A subsequent study (PMID 7998661) found no adverse reactions to MMR in egg-allergic children, but does not directly address the gelatin component combination.
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 40276512 · Frontiers in immunology (2025) — Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.
does_not_resolve 8473675 · The Journal of allergy and clinical immu (1993) — Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
refutes_node 7998661 · Annals of allergy (1994) — Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children.
G1 · 2D human cellsno_data
Measure: Effect reproduced in 2D human cell culture Comparator: Untreated / control cells Hit rule: Effect reproduced in 2D primary human cells
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis 2D human cells animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis 2D human cells not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G2 · Organoid / chipno_data
Measure: Effect reproduced in organoid / organ-on-chip Comparator: Unexposed organoid Hit rule: Effect reproduced in a 3D organoid / organ-on-chip system
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Organoid / chip animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Organoid / chip not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
H1 · Block in vitro / in vivono_data
Measure: Blocking the mediator/mechanism prevents the effect Comparator: Control intervention Hit rule: Blocking the mechanism prevents or reverses the effect (not with a control intervention)
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Block in vitro / in vivo intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Block in vitro / in vivo no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-07
Clinical / animal / host 7/7 evaluated
E10 · Host-line dependenceno_data
Measure: Effect depends on host line/cell type Comparator: Susceptible host line Hit rule: Effect is restricted to a defined host line / genotype, not universal
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis mechanism Host-line dependence in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Host-line dependence not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G3 · Animal, clinical routeno_data
Measure: Effect in animal via the clinical route of administration Comparator: Vehicle, same route Hit rule: Effect reproduced in an animal using the clinical route of administration
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Animal, clinical route animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Animal, clinical route not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G4 · Susceptible animalno_data
Measure: Effect in a susceptible animal model Comparator: Non-susceptible model Hit rule: Effect in a defined susceptible animal model
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Susceptible animal animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Susceptible animal not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G5 · Replication across labsno_data
Measure: Effect replicated in an independent lab Comparator: Original result Hit rule: The key effect is replicated in an independent laboratory
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Replication across labs animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Replication across labs not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G6 · Blinded scoringno_data
Measure: Outcomes scored blinded Comparator: Unblinded reference Hit rule: Primary outcomes scored by a blinded assessor
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Blinded scoring animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Blinded scoring not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G7 · Experimental time courseno_data
Measure: Effect follows a defined experimental time course Comparator: No-exposure time course Hit rule: The effect's onset/offset follows a defined experimental time course
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Experimental time course animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Experimental time course not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
I4 · Susceptibility traitno_data
Measure: A host trait / marker defines susceptibility Comparator: Trait-negative hosts Hit rule: A defined host trait / marker enriches for susceptibility
Finding: no evidence found
Cited: (none)
supporting: MMR vaccine Anaphylaxis Susceptibility trait coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: MMR vaccine Anaphylaxis Susceptibility trait inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
How this was built
Per node: a supporting and a mirror PubMed query built from the node's measure / population / comparator / hit_rule; top hits fetched (title + abstract); each record classified (supports / refutes / ambiguous) by xAI with a heuristic fallback; a per-node synthesis is generated strictly from the retrieved PMIDs; the node status is then rolled up to C1–C6. Full query provenance is shown per node above. Reproduce the build: python -m evidence_run. Data: data/evidence_run/state.json.